Background. Primary non-adherence refers to the patient not redeeming a prescribed medication at some point during drug therapy. Research has mainly focused on secondary non-adherence. Prior to this study, the overall rate of primary non-adherence in general practice in Iceland was not known.
Introduction
Adherence to medication is key to ensuring effective pharmacological treatment in medical practice. The World Health Organization (WHO) sees this as a major public health issue. 1 Primary non-adherence refers to the patient not redeeming a prescribed medication at some point during drug therapy, whereas secondary non-adherence 2 focuses on whether the patients actually take their medicines as intended by the prescribing doctor, and if not, to what extent they follow the doctor's advice. Several studies have been published on primary non-adherence, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] most of them in recent years, although their number may seem moderate compared to the wealth of literature on secondary non-adherence. 13 Prior to this study, the rate of primary non-adherence in Iceland was not known. This is one of a few studies using prescription databases covering the whole population in a selected area to study this important topic.
In February 2010, the Icelandic Ministry of Health and Welfare published a regulation (No. 140/2010), which took effect on 1 March 2010, amending the existing regulation concerning the cover of The Icelandic Health Insurance for patients' drug costs. These amendments increased patient copayment moderately for drugs not reimbursed in full, i.e. by an amount corresponding to €1 or €3 in the respective copayment categories (depending on patient characteristics). Furthermore, within certain drug classes as defined by the WHO's anatomical therapeutic chemical (ATC) classification system, 17 only the cheapest analogues would be covered. This change occurred not long after the deep economic crisis started in Iceland and the question was raised by policy makers whether increased patient copayment and economic recession, with a resulting fall in purchasing power of the general public, caused increased non-redemption of prescriptions. 18 Several studies have found an association between higher copayment and lower adherence or have reported that insufficient funds or a low socio-economic status may, in a number of cases, have been the reason for patients' failure to have their prescriptions dispensed. 4-7, 9, 11, 12, 15 Nevertheless, low income is not always predictive of primary non-adherence. 13 There may be various other reasons for non-adherence, including the patient-physician relationship (which can have an influence), previously experienced or suspected adverse reactions, difficulties in access to pharmacies or lack of transportation, dissatisfaction with the explanation of the medical problem, unclear instructions, patients' wish to gain control or medicine no longer needed. 5-7, 11, 12, 16 Whatever the reason for non-redemption of prescriptions, primary non-adherence is a part of the non-adherence problem that needs to be studied further.
The aim of this study was first to determine the rate of primary non-adherence to selected groups of drugs in general practice; second, to test in the same drug classes whether a moderate increase in patient copayment influenced primary non-adherence; and third, to examine the difference in primary non-adherence between patient copayment groups (general patients, children, disability pensioners and old-age pensioners).
Methods

Design and setting
The Primary Health Care of the Capital Area (PHCCA) includes most of the primary health-care centres in Reykjavik and nearby municipalities with a population of 200 000. Prescriptions are almost exclusively issued electronically and are either sent electronically to the pharmacy or printed for the patient to take to the pharmacy. PHCCA operates a Primary Health Care database (PHCD) of electronic medical records (including prescriptions) from its 15 centres and from an independent primary health-care centre. In total, 22 991 prescriptions issued by 140 physicians at 16 primary health-care centres for 21 571 patients during two 4-week periods make up the collection.
All prescriptions dispensed by Icelandic pharmacies are sent electronically to the Icelandic Prescriptions Database of The Directorate of Health (IPD), which has been in operation since 2002. To find uncollected prescriptions, the data on issued prescriptions were linked with data for the same patient on dispensed prescriptions (21 420) contained in the IPD.
Prescriptions issued according to the PHCD during a period of 4 weeks in January, before the amendments to regulation no. 140/2010 took effect, were compared with prescriptions issued during a period of 4 weeks in April 2010 after the amendments had taken effect. In both time periods, prescriptions were followed up for 3 months from their date of issue. The usual supply for drugs used for chronic treatment is 3 months.
The Icelandic Health Insurance covers the patients' drug costs either in full or as stipulated for B-marked or E-marked drugs according to the regulation no. 140/2010. A few drugs are paid in full by the patients. Table 1 shows the copayment structure before and after the regulation came into effect on 1 March 2010 according to the small (B-marked) and moderate (E-marked) copayment groups.
As can be seen in Table 1 , the increase from March to April was mainly that the ceiling (maximum) for copayment went up by 400-550 Icelandic krónur (ISK) (€2.5-3) for general patients and less for concession patients.
Data collection
Data on all medicines in eight ATC classes prescribed electronically by general practitioners for their patients were extracted from the PHCD. Prescriptions for the drug classes shown in Table 2 were extracted. Table 2 also reviews the copayment category and other reasons for including each of the eight drug classes in the study. For the small-copayment (B-marked) group, drug classes calcium-channel blockers and agents acting on the renin-angiotensin system (C08 and C09) are combined as they are both used to treat hypertension, which is the most common cardiovascular disease and patients usually do not notice any symptoms if they drop their medications.
In accordance with the law, a unique personal identifier (ID) is allocated to every inhabitant by Registers Iceland. This personal ID number is always entered both when prescriptions are issued in the PHCD and dispensed prescriptions are recorded in the IPD, making it possible to uniquely link issued prescriptions to dispensed prescriptions. Prescription data stored in both databases include ATC classification of the prescribed drug, its Nordic product number, prescribing physician, prescription date, patient age and sex. These variables were used to validate the matching. Prescriptions dispensed within 3 months from the date of issue according to IPD were defined as redeemed and otherwise as non-redeemed. In addition, records of patient reimbursement groups in the PHCD were checked in order to differentiate between the disabled and the elderly because they are grouped together in the same copayment group in the IPD.
Data analysis
The difference between issued and dispensed prescriptions was defined as uncollected prescriptions (primary non-adherence), i.e. issued prescriptions in the PHCD not matching up with dispensed prescriptions in the IPD comprised the collection of non-dispensed prescriptions. The number of patients who received at least one prescription and had it dispensed was also counted in both periods. The percentage of non-redeemed prescriptions was calculated and the rate of non-redemption for each drug class compared using two-tailed chi-square test. Odds ratios (OR) and 95% confidence intervals (CI) for the risk of not redeeming a prescription, as a measure of primary non-adherence by copayment groups, were calculated for all drug classes in both January and April, using general patients as a reference. Statistical analyses were conducted with IBM SPSS Statistics version 19.0 (IBM Corporation, Armonk, NY). When referring to significant difference in this paper, it should be understood as statistical significance (set at 0.05).
Results
The overall rate of primary non-adherence among the patients who were prescribed medications in ATC classes blood-glucose-lowering drugs, excluding Patients seldom experience any symptoms even if they discontinue the treatment. Small Calcium-channel blockers (C08) + agents acting on the renin-angiotensin system (C09)
The patient usually does not notice any symptoms after discontinuation of the drug treatment. Antidepressants (N06A)
Time lag between first intake and effect, between full effect and lack of effect if discontinued. Abrupt discontinuation may cause adverse reactions. Moderate Anti-inflammatory and anti-rheumatic products, non-steroids (M01A) Some probability of adverse effects, discontinuation can lead to reappearance of rheumatic pain Paid in full by patient Antibacterials for systemic use (J01) Intended for short-term (often symptomatic) treatment insulins (A10B), calcium-channel blockers + agents acting on the renin-angiotensin system (C08 + C09), antibacterials (J01), anti-inflammatory and anti-rheumatic products, non-steroids (M01A), antipsychotics (N05A), antidepressants (N06A) and anti-glaucoma preparations and miotics (S01E) during these two periods of 4 weeks was 6.2% (1339 out of 21 571 patients) for both periods combined, i.e. 6.9% in January (758 patients out of 10 954) and 5.5% in April (581 patients out of 10 617), after an increase in patient copayment. In both periods, 61% of all patients issued a prescription were female. No significant gender differences were observed in either study period (7.0% for females and 6.8% for males) in January and (5.4% for females and 5.6% for males) in April. The non-redemption rate ranged (i) from 6.2% for general patients to 8.8% for old-age pensioners in January and (ii) from 5.3% for general patients to 5.7% for both old-age and disability pensioners in April.
When studying the number of prescription items, as opposed to the number of patients, the overall rate of primary non-adherence was 7.6% in January and 6.1% in April. The rate for prescription items was slightly lower in April (6.1%) than in January (7.6%) in spite of the increased patient copayment for drugs with small or moderate copayment. Table 3 shows that the rate of prescription items not redeemed as a percentage of all issued prescriptions is lower for all drug groups in April than in January regardless of copayment category. Calcium-channel blockers + agents acting on the renin-angiotensin system (C08 + C09), anti-inflammatory and anti-rheumatic products (M01A) and antipsychotics (N05A) had significantly lower non-redemption rate in April than in January. When comparing non-redemption rates in each of the four copayment groups within each drug class, no statistically significant difference was observed between January and April (data not shown).
The number of issued and non-redeemed prescriptions for drugs in the aforementioned ATC classes by copayment groups and time periods is shown in Table 4 . For all drug classes except antidepressants, NSAIDs (M01A) and antibacterials, it was not possible to include children as they were either too few or not using the drugs at all. For the anti-glaucoma preparations and miotics, a statistical test could not be performed due to dearth of data. The results in Table 4 are hereafter reported by degree of patient copayment.
No copayment (Health insurance pays the full amount): No statistically significant difference was observed between copayment groups for blood-glucose-lowering drugs (A10B) in either of the periods, although old-age pensioners had a primary non-adherence rate almost twice that of general patients. For antipsychotics (N05A), a statistically significant difference was observed in January, where there was a 9-fold difference between old-age pensioners and general patients (OR = 8.79; 95% CI = 2.80-27.57).
Small copayment (B-marked drugs): For the cardiovascular agents in ATC groups C08 and C09, the old-age pensioners had a significantly higher primary non-adherence rate. Even if their copayment ceiling is quite a bit lower, their primary non-adherence was ~1.6-fold that for general patients in both time periods (January: OR = 1.63; 95% CI = 1.20-2.21; April: OR = 1.57; 95% CI = 1.09-2.26). Another group with a small copayment are the antidepressants, and in both time periods, old-age pensioners had more than double the primary non-adherence rate compared to general patients (January: OR = 2.23; 95% CI = 1.55-3.21; April: OR = 2.08; 95% CI = 1.37-3.16). Disability pensioners also had a similarly higher primary non-adherence rate in January than general patients (OR = 1.60; 95% CI = 1.06-2.42). Moderate copayment (E-marked drugs): Anti-inflammatory and non-steroidal anti-rheumatic products (M01A) showed a lower primary non-adherence rate for old-age pensioners than for general patients. The OR of being non-adherent for old-age pensioners was 0.40 times that of general patients (95% CI = 0.22-0.74) in April, but not significantly lower in January.
Full payment by the patient: When the patients paid in full for the drug (antibacterials, J01), old-age pensioners showed a lower non-adherence rate. In April, the OR for being non-adherent was significantly lower, at 0.61 times the primary non-adherence of general patients (95% CI = 0.39-0.96).
Discussion
Main findings This is the first study of primary non-adherence in Iceland. The population studied were patients visiting a GP in the PHCCA who were issued a prescription for Anti-inflammatory and anti-rheumatic products, non-steroids (M01A) Changes marked primary non-adherence in general practice one or more medicines in two time periods. In previous reports on primary non-adherence, non-redemption of prescriptions varied widely from 2.5% 16 to >30% of all prescriptions.
14, 15 The range of primary non-adherence in this study was between 3.1% for antipsychotics in April and 11.5% for anti-glaucoma preparations and miotics in January.
The widely used group of antibacterials had the lowest primary non-adherence overall as could be expected because they are intended for short-term symptomatic treatment of infections and patients usually need them urgently. Anti-diabetic drugs, which had no copayment, and anti-hypertensives with a small copayment had the overall highest primary non-adherence. This could in part be due to their widespread use among old-age pensioners.
As could be expected, primary non-adherence did not increase when drugs were paid in full by the Health Insurance. However, contrary to what was expected, primary non-adherence turned out to be lower in April than in January for most of the ATC classes even if some of them had increased medication costs for the patients. A relationship between medication costs and primary non-adherence has been reported in prior studies. 6, 9, 11, 12, 15 Within each period of 4 weeks, primary non-adherence tended to be higher in the groups of old-age and disability pensioners, which could be an expression of both their frailty and economic vulnerability, although the reverse pattern was observed for NSAIDs and antibacterials. Reappearance of rheumatic pain might increase the need of old-age pensioners for NSAIDs. No obvious reason for lower primary non-adherence in this group of patients can be pointed out regarding antibacterials paid in full by all, calling for further research. Regarding children, delayed antibiotic treatment recommended in clinical guidelines for bacterial otitis media might be a partial explanation for higher primary non-adherence than might have been expected in this group of patients, as parents following the doctor's advice do not redeem the prescription when it becomes clear after the 72-hour delay that their child has improved. Studies are needed on the extent of this practice and whether there is a causal association between it and primary non-adherence. Concerning the old-age pensioners, it can also be assumed that they are prescribed a relatively greater number of all types of drugs and it is known that in this age group, polypharmacy is more prevalent than in other groups. 19 The elderly probably receive a greater number of prescriptions per person and each person is therefore at a higher risk of primary non-adherence than members of other age groups. A number of studies have found non-adherence to be lower in older patients, 3, 4, 7, [9] [10] [11] [12] 16 whereas other studies have shown opposite results. [13] [14] [15] In all patient groups, the additional burden placed on patients by increasing their copayment appeared to have had a minimal effect. It could mean that patients prioritized their prescription medications in relation to other necessary expenditures or that they regarded the additional payment as insignificant. Drugs as well as primary health-care services are known to have low price elasticity, 20 which means that patients will continue to purchase medicines even if prices increase substantially. This may explain why non-adherence did not increase.
Strengths and limitations
The main strength of this study was the broad coverage of the study population, increasing its generalizability. Additionally, the focus on studying drug classes with varying copayment and symptom relief versus chronic treatment purpose can be viewed as a strength. This was also a limitation as only eight ATC drug classes were studied; the study might have given different results if all drug classes had been analysed.
Some patients were issued more than one prescription in each period and the total number of patients was slightly lower than the total number of prescriptions (10 954 versus 11 661 in January, and 10 617 versus 11 330 in April). It cannot be excluded that a patient has redeemed a prescription for one medication but dropped another prescription issued at the same time. This could lead to an overestimation of non-adherence as non-adherent patients who are prescribed many medications during a short time span will inflate the primary non-adherence rate.
In order to reveal a possible difference that could be interpreted as cost-related non-dispensing owing to the increase in patient copayment, the proximity and differences between the two periods being compared were important. In this respect, a possible confounder could be the payments for cost of various activities in connection with Christmas celebrations due in January. These may have outweighed the possible negative effect of increased copayment for medications in April.
The size of the population of the Reykjavik area leads to small numbers of prescriptions in most of the drug classes studied. A lack of power to detect statistically significant differences was therefore observed for some comparisons that showed large differences, such as for antipsychotics and anti-diabetic drugs. In addition, only a limited number of valid socio-economic variables are available in the databases we used. The present copayment categories may have led to the grouping together of quite a broad degree of economic susceptibility, which hampered the study of the influence of copayment increases on different socio-economic groups.
Concerning the time frame, we opted for 3 months of follow-up of redemption of the prescriptions. Several researchers have reported that the majority of patients collect their prescriptions the same day or within 1 week after seeing the doctor 10, 13 and most within 3 months or less, 8, 10 although the time lapse can be longer. 10, 13 Thus, 3 months is considered adequate.
Implications
Adherence to treatment is a prerequisite for effect in any disease. Primary adherence is crucial for the initiation of therapy. It varies both between drug groups and patient copayment groups. For clinicians, both the magnitude of primary non-adherence and the lack of influence of cost increases on the patient, as revealed in our study, indicate the importance of using follow-up consultations to discuss adherence problems, not least in patients with chronic diseases. We found that a moderate increase in copayment did not affect primary adherence adversely. The problem of non-adherence is multifaceted and cannot be dealt with by simply lowering out pocket costs. It must be addressed in the doctor's surgery and possibly by other means of follow-up such as telephone calls. 8 Health economic research has shown that some amount of patient copayment leads to more rational use of health resources. Similarly, increasing drug copayment incrementally does not show an increase in primary non-adherence in any drug group, regardless of copayment level. If policy makers want to support optimal utilization of resources in health care, they should join clinicians in trying to improve adherence. A piece of software for detecting primary non-adherence by linkage of electronic prescriptions to dispensing records, as described in this study, could be developed in order to support doctors in improving adherence in their patients.
